UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dermatologic Reactions to Cancer Therapies

1st, 2019

Volltextzugriff (PDF)

Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

Journal of the American Academy of Dermatology, 2012-11, Vol.67 (5), p.1025-1039

2012

Volltextzugriff (PDF)

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

Journal of clinical oncology, 2019-10, Vol.37 (30), p.2746-2758

2019

Volltextzugriff (PDF)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e002435

2021

Volltextzugriff (PDF)

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients

Clinical cancer research, 2015-03, Vol.21 (6), p.1313-1320

2015

Volltextzugriff (PDF)

Ipilimumab in patients with cancer and the management of dermatologic adverse events

Journal of the American Academy of Dermatology, 2014-07, Vol.71 (1), p.161-169

2014

Volltextzugriff (PDF)

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Supportive care in cancer, 2011-08, Vol.19 (8), p.1079-1095

2011

Volltextzugriff (PDF)

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2010-03, Vol.28 (8), p.1351-1357

2010

Volltextzugriff (PDF)

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice

Supportive care in cancer, 2017-02, Vol.25 (2), p.651-660

2017

Volltextzugriff (PDF)

Pruritus Associated with Targeted Anticancer Therapies and Their Management

Dermatologic clinics, 2018-07, Vol.36 (3), p.315-324

2018

Volltextzugriff (PDF)

Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature

The oncologist (Dayton, Ohio), 2020-02, Vol.25 (2), p.140-149

2020

Volltextzugriff (PDF)

Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group

Supportive care in cancer, 2013-10, Vol.21 (10), p.2933-2948

2013

Volltextzugriff (PDF)

Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition

Journal of clinical oncology, 2012-07, Vol.30 (19), p.2375-2383

2012

Volltextzugriff (PDF)

PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients

Supportive care in cancer, 2023-06, Vol.31 (6), p.337-337, Article 337

2023

Volltextzugriff (PDF)

The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis

Journal of the American Academy of Dermatology, 2013-09, Vol.69 (3), p.e121-e128

2013

Volltextzugriff (PDF)

Mechanisms of cutaneous toxicities to EGFR inhibitors

Nature reviews. Cancer, 2006-10, Vol.6 (10), p.803-812

Lacouture, Mario E

2006

Volltextzugriff (PDF)

Scarring, Disfigurement, and Quality of Life in Long-Term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study

Journal of clinical oncology, 2012-07, Vol.30 (20), p.2466-2474

2012

Volltextzugriff (PDF)

Effects of epidermal growth factor receptor inhibitor‐induced dermatologic toxicities on quality of life

Cancer, 2010-08, Vol.116 (16), p.3916-3923

2010

Volltextzugriff (PDF)

A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies

Supportive care in cancer, 2018-04, Vol.26 (4), p.1169-1179

2018

Volltextzugriff (PDF)

Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic

American journal of clinical dermatology, 2013-08, Vol.14 (4), p.327-333

2013

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management

The oncologist (Dayton, Ohio), 2007-05, Vol.12 (5), p.610-621

2007

Volltextzugriff (PDF)

The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review

Breast cancer research and treatment, 2019-06, Vol.175 (2), p.267-276

2019

Volltextzugriff (PDF)

Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis

Journal of the American Academy of Dermatology, 2013-11, Vol.69 (5), p.708-720

2013

Volltextzugriff (PDF)

A multidisciplinary approach to optimizing care of patients treated with alpelisib

Breast (Edinburgh), 2022-02, Vol.61, p.156-167

2022

Volltextzugriff (PDF)

1 – 25 von 458

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(365)
Mit Volltextzugriff
(402)

Publikationsform

Sprache

Englisch
(458)
Japanisch
(38)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(254)
Science & Technology
(254)
Humans
(211)
Oncology
(178)
Dermatology
(119)
Female
(101)
Male
(92)
Antineoplastic Agents - Adverse Effects
(88)
Middle Aged
(74)
Aged
(65)
Adult
(60)
Neoplasms - Drug Therapy
(57)
Medicine
(48)
Quality Of Life
(48)
Medicine & Public Health
(46)
Cancer
(44)
Receptor, Epidermal Growth Factor - Antagonists & Inhibitors
(41)
Drug Eruptions - Etiology
(35)
Aged, 80 And Over
(32)
Antineoplastic Agents - Therapeutic Use
(32)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Dermatologic Reactions to Cancer Therapies

Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients

Ipilimumab in patients with cancer and the management of dermatologic adverse events

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice

Pruritus Associated with Targeted Anticancer Therapies and Their Management

Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature

Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group

Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition

PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients

The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis

Mechanisms of cutaneous toxicities to EGFR inhibitors

Scarring, Disfigurement, and Quality of Life in Long-Term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study

Effects of epidermal growth factor receptor inhibitor‐induced dermatologic toxicities on quality of life

A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies

Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic

Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management

The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review

Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis

A multidisciplinary approach to optimizing care of patients treated with alpelisib

Suchergebnisse filtern